Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GE confirms imminent job cuts

This article was originally published in Clinica

Executive Summary

After previously declining to comment on internal business plans aimed at boosting its bottom line, GE Healthcare has confirmed that it is set to make job cuts. A spokesperson for the firm told The Business Journal of Milwaukee that GE was to make an unspecified number of cuts in order to “strengthen the company to better perform in the current economic environment and position it for profitable long term growth”. Scrutiny had been placed on the Chalfont St Giles, UK-based firm since its poor Q3 results in October (see Clinica No 1326, p 21). The brunt of the cuts may be taken by the firm’s underperforming imaging unit – last month, GE’s medtech rival Philips announced that it was to axe 1,600 positions, with a high proportion of the cuts being in the imaging sector (see Clinica No 1329, p 3). GE employs around 46,000 people in around 100 countries.

You may also be interested in...

Alere aided by professional diagnostics sales in fourth quarter

Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.

Integra and Stout to work on expandable interbody device

Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.

Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials

Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts